retatrutide clinical trial results 2024 2025 retatrutide weight loss study Tirzepatide shows 47% greater vs. Wegovy Retatrutide Where to Get: Can

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with overweight or obesity and knee osteoarthritis, according to topline results from the TRIUMPH-4 trial

By activating these key metabolic pathways, it recalibrates appetite, enhances energy output, and boosts overall metabolic efficiency for a smoother, more empowered transformation experience

This Comment highlights emerging evidence and advocates for clinical strategies that prioritize muscle preservation to ensure the long-term success and safety of pharmacological weight management.

Glucagon-like peptide-1 receptor agonists show promise for reducing apnea-hypopnea index and body weight in patients with obstructive sleep apnea, offering new treatment options beyond PAP therapy.

While they are not designed as fertility treatments, their downstream benefits in weight loss, hormone balance, testosterone improvement, and sperm health could create a positive impact on overall reproductive function.

A study of more than 110,000 women found those who took popular GLP-1 drugs prescribed for obesity or diabetes had a lower risk of breast cancer.